- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evotec SE ADR (EVO)
Evotec SE ADR stock price live, this page displays NASDAQ EVO stock exchange data. View the EVO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Evotec SE ADR real time stock price chart below.
What Is the Evotec SE ADR Stock Price Today?
The Evotec SE ADR stock price today is 1.98.
What Is the Stock Symbol for Evotec SE ADR?
The stock symbol for Evotec SE ADR is "EVO."
What Stock Exchange Does Evotec SE ADR Trade On?
Evotec SE ADR is listed and trades on the NASDAQ stock exchange.
Is Evotec SE ADR a Good Stock to Buy?
Determining whether Evotec SE ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVO quote. (ISIN: US30050E1055)
What Is the Evotec SE ADR Stock Price Today?
The Evotec SE ADR stock price today is 1.98.
What Is the Stock Symbol for Evotec SE ADR?
The stock symbol for Evotec SE ADR is "EVO."
What Stock Exchange Does Evotec SE ADR Trade On?
Evotec SE ADR is listed and trades on the NASDAQ stock exchange.
Is Evotec SE ADR a Good Stock to Buy?
Determining whether Evotec SE ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVO quote. (ISIN: US30050E1055)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.98
2.08
52 wk Range
1.95
4.42
EVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.982.08
52 wk Range
1.954.42
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EVO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
3.79
Upside
+91.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
- Evotec AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Evotec AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Evotec AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
1 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.79
(+91.56% Upside)
Evotec SE ADR Earnings Call Summary for Q2/2026
- Evotec Q2 revenue fell 16% YoY to €143.5M; H1 revenue down 19% to €300.1M, with adjusted EBITDA losses of €20.8M and €42.7M respectively.
- Full-year 2026 guidance cut to €570M-€610M revenue and adjusted EBITDA loss of €70M-€105M, citing delayed partnership milestones rather than lost business.
- Management attributes 40% of revenue shortfall to delayed milestone payments, 45% to longer partnership timelines, expecting revenue to shift into 2027.
- Shares plunged 11.5% in premarket to $2.15, trading near 52-week lows despite positive commercial indicators showing 30% rise in inquiries and 45% proposal growth.
- Horizon transformation program targets €75M annual savings by end-2027, with 20-30% expected in 2026; new J.TRAIN technology launched but no material deals anticipated this year.
Last Updated: 2026-07-14, 09:02 a/m
Read Full TranscriptEarnings
Latest Release
May 06, 2026
EPS / Forecast
-0.39 / -0.18
Revenue / Forecast
181.69M / 227.65M
Compare EVO to Peers and Sector
Metrics to compare | EVO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | 0.4x | −0.4x | |
PEG Ratio | −0.48 | −0.09 | 0.00 | |
Price/Book | 0.9x | 3.3x | 2.6x | |
Price / LTM Sales | 0.8x | 4.4x | 3.0x | |
Upside (Analyst Target) | 61.2% | 161.9% | 54.6% | |
Fair Value Upside | Unlock | 13.7% | 9.7% | Unlock |
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Evotec SE ADR (EVO) Stock Price Today?
The Evotec SE ADR stock price today is 1.98 USD.
What Stock Exchange Does Evotec SE ADR Trade On?
Evotec SE ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Evotec SE ADR?
The stock symbol for Evotec SE ADR is "EVO."
What Is the Evotec SE ADR Market Cap?
As of today, Evotec SE ADR market cap is 716.27M USD.
What Is Evotec SE ADR's Earnings Per Share (TTM)?
The Evotec SE ADR EPS (TTM) is -1.09.
When Is the Next Evotec SE ADR Earnings Date?
Evotec SE ADR will release its next earnings report on Aug 13, 2026.
From a Technical Analysis Perspective, Is EVO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Evotec SE ADR Stock Split?
Evotec SE ADR has split 1 times.
How Many Employees Does Evotec SE ADR Have?
Evotec SE ADR has 4526 employees.
What is the current trading status of Evotec SE ADR (EVO)?
As of Jul 21, 2026, Evotec SE ADR (EVO) is trading at a price of 1.98 USD, with a previous close of 1.98 USD. The stock has fluctuated within a day range of 1.98 USD to 2.08 USD, while its 52-week range spans from 1.95 USD to 4.42 USD.
What Is Evotec SE ADR (EVO) Price Target According to Analysts?
The average 12-month price target for Evotec SE ADR is 3.79 USD, with a high estimate of 6.78885463 USD and a low estimate of 1.99611739 USD. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +91.56% Upside potential.
What Is the EVO Premarket Price?
EVO's last pre-market stock price is 2.07 USD. The pre-market share volume is 30.00, and the stock has decreased by 0.09, or 4.55%.
What Is the EVO After Hours Price?
EVO's last after hours stock price is 2.02 USD, the stock has decreased by 0.04, or 2.02%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.